{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:10:33Z","timestamp":1792426233039,"version":"4.5.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The addition of fludarabine to cyclophosphamide as a lymphodepleting regimen prior to CD19 chimeric antigen receptor (CAR) T-cell therapy significantly improved outcomes in patients with relapsed\/refractory (r\/r) B-cell acute lymphoblastic leukemia (B-ALL). Fludarabine exposure, previously shown to be highly variable when dosing is based on body surface area (BSA), is a predictor for survival in allogeneic hematopoietic cell transplantation (allo-HCT). Hence, we hypothesized that an optimal exposure of fludarabine might be of clinical importance in CD19 CAR T-cell treatment. We examined the effect of cumulative fludarabine exposure during lymphodepletion, defined as concentration-time curve (AUC), on clinical outcome and lymphocyte kinetics. A retrospective analysis was conducted with data from 26 patients receiving tisagenlecleucel for r\/r B-ALL. Exposure of fludarabine was shown to be a predictor for leukemia-free survival (LFS), B-cell aplasia, and CD19-positive relapse following CAR T-cell infusion. Minimal event probability was observed at a cumulative fludarabine AUCT0\u2212\u221e \u226514 mg*h\/L, and underexposure was defined as an AUCT0\u2212\u221e &amp;lt;14 mg*h\/L. In the underexposed group, the median LFS was 1.8 months, and the occurrence of CD19-positive relapse within 1 year was 100%, which was higher compared with the group with an AUCT0\u2212\u221e \u226514 mg*h\/L (12.9 months; P &amp;lt; .001; and 27.4%; P = .0001, respectively). Furthermore, the duration of B-cell aplasia within 6 months was shorter in the underexposed group (77.3% vs 37.3%; P = .009). These results suggest that optimizing fludarabine exposure may have a relevant impact on LFS following CAR T-cell therapy, which needs to be validated in a prospective clinical trial.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006700","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T19:18:36Z","timestamp":1644347916000},"page":"1969-1976","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":89,"title":["Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8423-0182","authenticated-orcid":false,"given":"Linde","family":"Dekker","sequence":"first","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friso G.","family":"Calkoen","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilly","family":"Blok","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1626-353X","authenticated-orcid":false,"given":"Saskia R.","family":"Veldkamp","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coco","family":"De Koning","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Spoon","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Admiraal","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hoogerbrugge","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Vormoor","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1825-1890","authenticated-orcid":false,"given":"H. Josef","family":"Vormoor","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"},{"name":"University Medical Center Utrecht, Utrecht, The Netherlands;"},{"name":"Newcastle University, Newcastle upon Tyne, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-2893","authenticated-orcid":false,"given":"Henk","family":"Visscher","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bierings","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Van Der Vlugt","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"Van Tinteren","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3448-7665","authenticated-orcid":false,"given":"A. Laura","family":"Nijstad","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"},{"name":"University Medical Center Utrecht, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"},{"name":"University Medical Center Utrecht, Utrecht, The Netherlands;"},{"name":"Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim C. M.","family":"Van Der Elst","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Lindemans","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Nierkens","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"},{"name":"University Medical Center Utrecht, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"issue":"9967","key":"2022032515285894300_B1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet."},{"issue":"5","key":"2022032515285894300_B2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"issue":"26","key":"2022032515285894300_B3","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood."},{"issue":"15","key":"2022032515285894300_B4","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol."},{"issue":"25","key":"2022032515285894300_B5","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood."},{"issue":"12","key":"2022032515285894300_B6","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia."},{"issue":"303","key":"2022032515285894300_B7","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med."},{"issue":"12","key":"2022032515285894300_B8","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1038\/s41375-020-0831-z","article-title":"Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r\/r B-ALL children","volume":"34","author":"Pan","year":"2020","journal-title":"Leukemia."},{"issue":"22","key":"2022032515285894300_B9","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv."},{"issue":"16","key":"2022032515285894300_B10","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med."},{"issue":"24","key":"2022032515285894300_B11","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2022032515285894300_B12","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest."},{"key":"2022032515285894300_B13","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor-modified T cells HHS public access","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med."},{"issue":"32","key":"2022032515285894300_B14","doi-asserted-by":"crossref","first-page":"33961","DOI":"10.18632\/oncotarget.5582","article-title":"Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget."},{"issue":"3","key":"2022032515285894300_B15","doi-asserted-by":"crossref","first-page":"e4749","DOI":"10.1371\/journal.pone.0004749","article-title":"Fludarabine modulates immune response and extends in\u00a0vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma","volume":"4","author":"Wallen","year":"2009","journal-title":"PLoS One."},{"issue":"2","key":"2022032515285894300_B16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.4049\/jimmunol.0804159","article-title":"Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy","volume":"184","author":"Condomines","year":"2010","journal-title":"J Immunol."},{"issue":"5","key":"2022032515285894300_B17","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-018-0715-9","article-title":"Population pharmacokinetics of fludarabine in children and adults during conditioning prior to allogeneic hematopoietic cell transplantation","volume":"58","author":"Langenhorst","year":"2019","journal-title":"Clin Pharmacokinet."},{"issue":"14","key":"2022032515285894300_B18","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/bloodadvances.2018029421","article-title":"Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes","volume":"3","author":"Langenhorst","year":"2019","journal-title":"Blood Adv."},{"key":"2022032515285894300_B19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jchromb.2017.04.025","article-title":"Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS\/MS for exposure monitoring in hematopoietic cell transplantation conditioning","volume":"1055-1056","author":"Punt","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"issue":"1","key":"2022032515285894300_B20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/biomet\/77.1.147","article-title":"Martingale-based residuals for survival models","volume":"77","author":"Therneau","year":"1990","journal-title":"Biometrika."},{"issue":"4","key":"2022032515285894300_B21","first-page":"1136","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"5","author":"Pasquini","year":"2021","journal-title":"Blood Adv."},{"key":"2022032515285894300_B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes following CAR T-cell Therapy","author":"Fabrizio","journal-title":"Blood Adv."},{"issue":"5","key":"2022032515285894300_B23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med."},{"issue":"11","key":"2022032515285894300_B24","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1038\/s41375-021-01196-3","article-title":"Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia","volume":"35","author":"Perica","year":"2021","journal-title":"Leukemia."},{"issue":"17","key":"2022032515285894300_B25","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood."},{"key":"2022032515285894300_B26","first-page":"37","article-title":"High IL-15 serum concentrations are associated with response to CD19 CAR T-cell therapy and robust in\u00a0vivo CAR T-cell kinetics","volume":"136","author":"Gauthier","year":"2020"},{"issue":"4","key":"2022032515285894300_B27","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/bmt.2016.322","article-title":"Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML\/MDS patients","volume":"52","author":"Andersson","year":"2017","journal-title":"Bone Marrow Transplant."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/7\/1969\/1882804\/advancesadv2021006700.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/7\/1969\/1882804\/advancesadv2021006700.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T15:53:38Z","timestamp":1648223618000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/7\/1969\/483864\/Fludarabine-exposure-predicts-outcome-after-CD19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,4,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006700","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]}}}